Typhoid Clinical Trial - Evaluation of the Vi Polysaccharide Vaccine

Status Completed

Clinical Trial Summary

This study is part of the International Vaccine Institute's (IVI's) typhoid Vi demonstration project that aims to accelerate the rational introduction of Vi vaccines in typhoid endemic countries. The purpose of this study is to determine the effectiveness of the Vi vaccine following a mass typhoid immunization campaign in an endemic area in Kolkata, India. The cost-effectiveness of the Vi vaccination and the logistic feasibility of a mass typhoid immunization campaign will also be evaluated.

Clinical Trial Description

Typhoid fever is a major cause of morbidity worldwide. The disease predominantly affects school-aged children, is more prevalent in urban areas, may last for several weeks and can lead to serious complications. Management of this disease is further complicated by the emergence of multi-drug resistant strains. Vaccination of high risk populations is considered the most promising strategy for the control of typhoid fever. The Vi polysaccharide vaccine has been targeted for accelerated introduction into public health programs since it has been shown to have consistent efficacy results even in areas of high typhoid incidence, is given as a single dose, lacks patent protection and requires less strict cold chain requirements.

This project attempts to evaluate a new vaccination strategy for residents of endemic areas. A cluster-randomized trial involving the Vi polysaccharide vaccine and an active control (Hepatitis A) was designed to determine the effectiveness and the feasibility of providing Vi vaccine under actual programmatic conditions in 2 contiguous urban wards in Kolkata. The vaccines used in this study are internationally produced and locally licensed. A 1 year pilot phase will precede the actual Vi-demonstration project. Surveillance for typhoid fever cases will continue after the mass immunization campaign. A passive surveillance system to evaluate adverse events following immunization will be implemented. Socio-economic studies will be conducted in parallel to the effectiveness evaluation. The knowledge, attitudes, beliefs and practices among parents and health care providers regarding typhoid illness, treatment and prevention will be assessed. Logistic, feasibility and vaccine costs will also be determined. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00125008
Study type	Interventional
Source	International Vaccine Institute
Contact
Status	Completed
Phase	Phase 4
Start date	May 2003
Completion date	January 2008

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03312699` - Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort	Phase 1
Completed	`NCT01405521` - Understanding Typhoid Disease After Vaccination	Phase 2
Completed	`NCT00131833` - Typhoid Vi Vaccine Effectiveness in Hechi, Guangxi, China	Phase 4
Completed	`NCT00125047` - Combined Vi Vaccination and Health Education Program on the Burden of Typhoid in Childhood	Phase 4
Not yet recruiting	`NCT05771779` - Co-administration Study of OCV, TCV and MR	Phase 3
Completed	`NCT01466387` - A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults	Phase 3
Active, not recruiting	`NCT03933098` - Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine	Phase 3
Completed	`NCT00679172` - Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults	Phase 2
Recruiting	`NCT04878549` - Transcriptomic Responses for the Identification of Pathogens
Completed	`NCT02645032` - Safety and Immunogenicity of a Vi-DT Typhoid Conjugate Vaccine	Phase 1
Recruiting	`NCT05475379` - Non-inferiority Trial of Locally Manufactured Typhoid Conjugate Vaccine 'Typhocon' in Bangladesh	Phase 1/Phase 2
Completed	`NCT04204096` - Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III)	Phase 3
Active, not recruiting	`NCT03299426` - Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi	Phase 3
Completed	`NCT01019083` - Studies of Immune Responses to Orally Administered Vaccines in Developing Country	Phase 1/Phase 2
Completed	`NCT03614533` - Typhoid Conjugate Vaccine Trial Among Children Younger Than 2 Years in Ouagadougou, Burkina Faso	Phase 2
Completed	`NCT00131820` - Introduction of the Vi Polysaccharide Typhoid Vaccine in Hue City, Central Vietnam	Phase 4
Completed	`NCT03527355` - Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms